INTRODUCTION: We previously reported data on the safety, tolerability, and recommended phase II dose of obatoclax mesylate in conjunction with topotecan in patients with advanced solid tumor malignancies. Preliminary efficacy data suggested activity in patients with recurrent small cell lung cancer (SCLC). Based on these data, we performed a phase II study of obatoclax mesylate plus topotecan in patients with relapsed SCLC to assess efficacy. METHODS: This was an open-label, single-arm, phase II extension of obatoclax mesylate plus topotecan in patients with relapsed SCLC. Obatoclax mesylate was given intravenously (IV) at a dose of 14mg/m(2) on days 1 and 3 with IV topotecan at 1.25mg/m(2) on days 1-5 of an every 3-week cycle. The primary end-point of this study was overall response rate. RESULTS: Nine patients with recurrent SCLC were enrolled into the first stage of the study. Patients received a median of 2 cycles of treatment. All patients were evaluable for the primary end-point of overall response. There were no partial or complete responses. Five patients (56%) had stable disease. The remaining four patients (44%) developed progressive disease. The most common grade 3 or 4 adverse events included thrombocytopenia (22%), anemia (11%), neutropenia (11%), and ataxia (11%). CONCLUSION: Obatoclax mesylate added to topotecan does not exceed the historic response rate seen with topotecan alone in patients with relapsed SCLC following the first-line platinum-based therapy.
INTRODUCTION: We previously reported data on the safety, tolerability, and recommended phase II dose of obatoclax mesylate in conjunction with topotecan in patients with advanced solid tumor malignancies. Preliminary efficacy data suggested activity in patients with recurrent small cell lung cancer (SCLC). Based on these data, we performed a phase II study of obatoclax mesylate plus topotecan in patients with relapsed SCLC to assess efficacy. METHODS: This was an open-label, single-arm, phase II extension of obatoclax mesylate plus topotecan in patients with relapsed SCLC. Obatoclax mesylate was given intravenously (IV) at a dose of 14mg/m(2) on days 1 and 3 with IV topotecan at 1.25mg/m(2) on days 1-5 of an every 3-week cycle. The primary end-point of this study was overall response rate. RESULTS: Nine patients with recurrent SCLC were enrolled into the first stage of the study. Patients received a median of 2 cycles of treatment. All patients were evaluable for the primary end-point of overall response. There were no partial or complete responses. Five patients (56%) had stable disease. The remaining four patients (44%) developed progressive disease. The most common grade 3 or 4 adverse events included thrombocytopenia (22%), anemia (11%), neutropenia (11%), and ataxia (11%). CONCLUSION:Obatoclax mesylate added to topotecan does not exceed the historic response rate seen with topotecan alone in patients with relapsed SCLC following the first-line platinum-based therapy.
Authors: A Ziegler; G H Luedke; D Fabbro; K H Altmann; R A Stahel; U Zangemeister-Wittke Journal: J Natl Cancer Inst Date: 1997-07-16 Impact factor: 13.506
Authors: J von Pawel; U Gatzemeier; J L Pujol; L Moreau; S Bildat; M Ranson; G Richardson; C Steppert; A Rivière; I Camlett; S Lane; G Ross Journal: J Clin Oncol Date: 2001-03-15 Impact factor: 44.544
Authors: A Ardizzoni; H Hansen; P Dombernowsky; T Gamucci; S Kaplan; P Postmus; G Giaccone; B Schaefer; J Wanders; J Verweij Journal: J Clin Oncol Date: 1997-05 Impact factor: 44.544
Authors: Paul K Paik; Charles M Rudin; Andrew Brown; Naiyer A Rizvi; Naoko Takebe; William Travis; Leonard James; Michelle S Ginsberg; Rosalyn Juergens; Susan Markus; Leslie Tyson; Sara Subzwari; Mark G Kris; Lee M Krug Journal: Cancer Chemother Pharmacol Date: 2010-02-18 Impact factor: 3.333
Authors: M Vogler; K Weber; D Dinsdale; I Schmitz; K Schulze-Osthoff; M J S Dyer; G M Cohen Journal: Cell Death Differ Date: 2009-04-24 Impact factor: 15.828
Authors: Rathi N Pillai; Joseph Aisner; Suzanne E Dahlberg; John S Rogers; Robert S DiPaola; Seena Aisner; Suresh S Ramalingam; Joan H Schiller Journal: Cancer Chemother Pharmacol Date: 2014-05-24 Impact factor: 3.333
Authors: Mariacarmela Santarpia; Maria Grazia Daffinà; Niki Karachaliou; Maria González-Cao; Chiara Lazzari; Giuseppe Altavilla; Rafael Rosell Journal: Transl Lung Cancer Res Date: 2016-02
Authors: Melisa A Martínez-Paniagua; Stavroula Baritaki; Sara Huerta-Yepez; Vianney F Ortiz-Navarrete; Cesar González-Bonilla; Benjamin Bonavida; Mario I Vega Journal: Cell Cycle Date: 2011-08-15 Impact factor: 4.534